A recent study published in JAMA reveals a significant increase in insurance denials for brand-name drugs. Between 2018 and 2024, denials for these medications without generic alternatives rose by 67 percent. Researchers examined over two million prescription fill attempts to reach this conclusion.

The study found that certain medications, such as GLP-1 weight-loss drugs, faced particularly high denial rates. Formulary exclusions were a common reason for these rejections, with nearly one-third of initial fill attempts being turned down. Further details on the study's findings, including the impact on patients, are available from the source.

The study's results provide insight into the growing issue of insurance restrictions on prescription medications.